cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.17510469
title: Daily Soil Moisture and Its Driving Factors (Static and Dynamic) in Three Watersheds: Dali River Basin, Anning River Basin, and Jiangjia Ravine (2003-2022)

description: The dataset (file S1, S2, and S3) includes the following variables from 2003 to 2022:





Daily soil moisture




Dynamic factors: Precipitation (Prec), surface wind speed (WS), relative humidity (RHU), 2m air temperature (T2m), and actual evaporation (AE)




Static factors: Slope (β), Aspect (Asp), Topographic Wetness Index (TWI), Soil texture (Sand, Silt, Clay), and Normalized Difference Vegetation Index (NDVI)
DOI: 10.6084/m9.figshare.30514913
title: Kanki Diabetes Manuscript Supplementary Figures Sept 2025

description: Kanki Diabetes Manuscript Supplementary Figures Sept 2025
DOI: 10.6084/m9.figshare.30514913.v1
title: Kanki Diabetes Manuscript Supplementary Figures Sept 2025

description: Kanki Diabetes Manuscript Supplementary Figures Sept 2025
DOI: 10.15468/dl.a36e9w
title: Occurrence Download

description: A dataset containing 2162 species occurrences available in GBIF matching the query:
{
 "and" : [
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "TaxonKey is Eucommia ulmoides"
 ]
}

 The dataset includes 2162 records from 92 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012305-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.p4wx4q
title: Occurrence Download

description: A dataset containing 14700 species occurrences available in GBIF matching the query:
{
 "PublishingOrg" : [
 "is cdef28b1-db4e-4c58-aa71-3c5238c2d0b5"
 ]
}

 The dataset includes 14700 records from 3 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012306-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.4230/dblp.rdf.ntriples.2025-11-01
title: dblp computer science bibliography – Monthly Snapshot RDF/N-Triple Release of November 2025

description: This file contains all the dblp RDF/N-Triple data in a single file. The dblp computer science bibliography is the open indexing service and knowledge graph of the computer science community. dblp provides quality-checked and curated bibliographic metadata on major computer science journals, proceedings, and monographs, as well as metadata and identifiers about their authors and the venues they have been published in.
DOI: 10.4230/dblp.xml.2025-11-01
title: dblp computer science bibliography – Monthly Snapshot XML Release of November 2025

description: This file contains all the raw dblp XML record data in a single file. The dblp computer science bibliography is the open indexing service and knowledge graph of the computer science community. dblp provides quality-checked and curated bibliographic metadata on major computer science journals, proceedings, and monographs, as well as metadata and identifiers about their authors and the venues they have been published in.
DOI: 10.6084/m9.figshare.29208974.v2
title: <i>Caenorhabditis briggsae</i> Mitochondrial Genome Assemblies of CaeNDR Whole-Genome Sequencing Data

description: This dataset contains 1927 mitochondrial genome assemblies for <i>Caenorhabditis briggsae</i>, generated from whole-genome sequencing data (<i>C. briggsae</i> releases 20250626) downloaded from the CaeNDR. The dataset include:<b>Genome sequences</b> (FASTA format)<b>Assembly graph</b> (GFA format)<b>Annotation</b> (GFF3 format)<b>CDS</b> (FFN format)<b>Protein sequences</b> (FAA format)The data downloaded from CaeNDR consisted of quality-controlled and aligned whole genome reads. Reads aligned to the mitochondrial genome were extracted and subjected to an initial assembly using SPAdes (v4.0.0) with a k-mer range of 127, 117, 107, 97, 87, and 77. If subsequent annotation revealed anomalies—such as abnormal gene lengths, gene counts, or gene orders—the assembly graph was manually inspected. Based on this inspection, the mitochondrial genome was either resolved manually, reassembled using Unicycler (v0.5.1) or NOVOPlasty (v4.3.5), or deemed unassemblable. The CaeNDR 20250626 release includes 2,022 strains, of which 1,927 are successfully assembled and annotated, while 95 failed assembly (63 due to the presence of complex NCR4, 2 due to insufficient sequencing depth and 30 identified as mixed strains)
DOI: 10.15151/esrf-es-2234936339
title: CHRONOS (continuation)

description: The CHRONOS BAG at ESRF is a specialized access mode designed for long-term in situ synchrotron experiments. Its mission is to capture slow processes in real time by enabling continuous X-ray imaging over extended periods. The principle relies on automated, scheduled scans that allow researchers to track dynamic changes in materials under controlled conditions with implications for numerous scientific and industrial fields. In geosciences, it enhances our understanding of fault mechanics, fluid-rock interactions, and carbon sequestration. In material science, it provides insights into creep, fatigue, and phase changes. By bridging timescales and automating data collection, CHRONOS advances synchrotron techniques and opens new possibilities for studying time-dependent natural and manufactured systems.
DOI: 10.15151/esrf-es-2231561909
title: Belgian BAG

description: The Belgium BAG includes groups situated at four Flemish universities: Antwerpen, Brussels, Ghent and Leuven. The proposed projects are highly diverse,
 including viral, prokaryotic and eukaryotic proteins with a strong focus on targets and processes of biomedical relevance. Many projects deal with membrane
 proteins, cell surface receptors and protein-protein complexes. Central to the research in the BAG associated groups is the employment of integrative methods in
 structural biology combining X-ray crystallography, SAXS, and electron microscopy. Many crystals in the various proposed projects are small in size and radiation
 sensitive, requiring the use of the high brilliance MX beam lines, preferably with micro-focused X-rays.
DOI: 10.15151/esrf-es-2232202253
title: Advanced Photon Source, Sector 21 - The Life Sciences Collaborative Access Team (LS-CAT) - CAT Member Macromolecular Crystallography

description: The Life Sciences Collaborative Access Team (LS-CAT) provides Macromolecular Crystallography support to our CAT members from seven Universities in the USA, including Northwestern University, University of Michigan, Wayne State University, Michigan State University, University of Wisconsin, Vanderbilt University, and University of Illinois at Chicago, and also to General Users. With a one-year dark period approaching for the upgrade of the Advanced Photon Source (APS-U), we sought beam time for our CAT Member laboratories at ESRF by way of a Block Allocation Group Proposal, in order to keep supporting their research and their ability to secure future funding. LS-CAT has organized our CAT Members (~80 PIs and their laboratory personnel) into this BAG Proposal, and in order to streamline the process for our CAT Members, and for the Staff of Lightsources to which we are applying for access to beam time, only LS-CAT Staff Crystallographers will be collecting and managing the data.
DOI: 10.15151/esrf-es-2233749970
title: The Israeli BAG

description: This Summary will only portray a very limited scope of the BAG proposal due to its size and more information will be available in the Global Summary. We plan establish a comprehensive structural narrative for the assembly and entry of viruses from the Bunyavirales family using X-ray crystallography, biophysics, biochemistry, and molecular virology. Using X-ray crystallography to obtain the 3D structure of GN and GC in different conformations and from different bunyavituses. We will pursue a structure of GN or GC bound to a neutralizing antibody to obtain new data for vaccine design. In the SAXS arena, we plan to continue the study on MT (microtubules) and expand the experiments with different nucleotide type and concentrations, (GTP, GDP, GMPCPP, and GMPPCP, GTP-gammaS). We will perform at selected points SEC-SAXS experiments in the presence of full-length tau (4RL). Our preliminary data revealed that 4RL promote MT assembly at 36C and of single tubulin rings at low temperatures.
DOI: 10.15151/esrf-es-2227848949
title: Novel high pressure phase evolution in PbRhO3+x

description: We propose an investigation of the pressure dependent evolution of PbRhO3+x structures between 14 and 24 GPa under stoichiometric and excess oxygen conditions. This is carried out in order to elucidate the transformation mechanisms between three newly synthesised PbRhO3+x phases; pyrochlore Pb2Rh2O7, YMnO3 type PbRhO3 and perovskite PbRhO3. A pyrochlore → YMnO3 type → perovskite pressure dependent phase sequence has not been reported in other systems. The understanding of this mechanism has implications for pressure dependent ABO3 phase relationships as well as the stabilisation mechanisms of YMnO3 type compounds, an attractive structure type for multiferroic materials.
DOI: 10.15151/esrf-es-2233034692
title: Very Long-Distance MLL Development and in-situ & in-operando Setups for X-ray Nanodiffraction Analysis of Thin Films and Energy Components

description: The project focuses on the development of multilayer Laue lenses (MLLs) for ID13. Previous experiments have already shown focal spot sizes down to ~23 nm with diffraction efficiencies up to about 29 %. The main instrumental goal of this LTP is the development of two types of MLL optics, namely (i) “very long-distance” with a focal length of up to ~150 mm, a working distance of &gt;100 mm (@ 12 keV) and an optics aperture of up to ~ 200 µm × 200 µm and (ii) “a new high resolution” lens pair with a focal spot size down to half of the present value, reaching ~10 nm. The MLLs will be used to perform (i) in-situ micromechanical tests on thin films and fibers using a dedicated indenter and (ii) in-operando electro-chemo-mechanical tests on solid state batteries (SSBs). For this purpose, the indenter from MI-1355 will be further developed by implementing new sample mounts, wedge and flat-punch tips and tensile option. Additionally, an adaptable in-operando cell to test SSBs will be designed.
DOI: 10.6084/m9.figshare.30231314
title: Management of patients starting treatment with second-generation antipsychotics: insights from a European retrospective real-world analysis

description: Understanding real-life management of mental health disorders is crucial for enabling effective social and healthcare interventions. This retrospective real-world study investigated differences in the management of young adults (&lt;30 years) and adults (≥30 years) starting treatment with second-generation antipsychotics (SGAs) in Italy, Spain and Poland. Patients’ characteristics, treatment and safety profile and healthcare resource utilisation were analysed from general practitioners’ and psychiatrists’ electronic medical records and from pharmacy prescription records. The main analysis was stratified by age, but stratification by SGA molecule and a focus on subjects with schizophrenia were also provided. A total of 530,587 subjects started treatment with SGAs. Throughout data sources, young adults accounted for from 17.8% to 30.2%; women were more represented among adults, who also had higher proportions of comorbid conditions. Young adults showed higher frequencies of switches (from 4.7% to 11.0% for young adults and from 2.9% to 8.6% for adults) and add-ons (from 2.5% to 5.6% for young adults and from 1.7% to 5.0% for adults) and exhibited slightly better adherence/persistence with the initial SGA. Distinct management behaviours were identified depending on age. A nuanced approach integrating tailored therapeutic strategies is needed to optimise long-term outcomes for patients requiring treatment with SGAs.
DOI: 10.6084/m9.figshare.30231314.v1
title: Management of patients starting treatment with second-generation antipsychotics: insights from a European retrospective real-world analysis

description: Understanding real-life management of mental health disorders is crucial for enabling effective social and healthcare interventions. This retrospective real-world study investigated differences in the management of young adults (&lt;30 years) and adults (≥30 years) starting treatment with second-generation antipsychotics (SGAs) in Italy, Spain and Poland. Patients’ characteristics, treatment and safety profile and healthcare resource utilisation were analysed from general practitioners’ and psychiatrists’ electronic medical records and from pharmacy prescription records. The main analysis was stratified by age, but stratification by SGA molecule and a focus on subjects with schizophrenia were also provided. A total of 530,587 subjects started treatment with SGAs. Throughout data sources, young adults accounted for from 17.8% to 30.2%; women were more represented among adults, who also had higher proportions of comorbid conditions. Young adults showed higher frequencies of switches (from 4.7% to 11.0% for young adults and from 2.9% to 8.6% for adults) and add-ons (from 2.5% to 5.6% for young adults and from 1.7% to 5.0% for adults) and exhibited slightly better adherence/persistence with the initial SGA. Distinct management behaviours were identified depending on age. A nuanced approach integrating tailored therapeutic strategies is needed to optimise long-term outcomes for patients requiring treatment with SGAs.
DOI: 10.6084/m9.figshare.30001057
title: The efficacy of metformin in counteracting olanzapine-induced hyperprolactinemia: an open-label prospective study

description: Prolactin elevation is a common adverse effect of antipsychotic medications. The study aimed to explore the potential of metformin in managing olanzapine-induced hyperprolactinaemia. A prospective study was designed to investigate the changes in prolactin levels over an eight-week metformin treatment. Thirty-one patients with schizophrenia (aged 18–60 years) on a stable dose of olanzapine for at least three months were enrolled. Participants received metformin at 1500 mg/day for eight weeks. Prolactin levels and metabolic parameters were measured at baseline and at weeks 2, 4, 6, and 8. After eight weeks of metformin intervention, prolactin levels significantly decreased from 39.7 ± 20.0 ng/mL at baseline to 35.7 ± 15.7 ng/mL (<i>p</i> = 0.005) with a moderate effect size (Cohen’s <i>d</i> = 0.545). Reductions in prolactin levels correlated positively with baseline prolactin levels (<i>r</i> = 0.72, <i>p</i> &lt; 0.001) and baseline glucose levels (<i>r</i> = 0.47, <i>p</i> = 0.008). Body weight, BMI, insulin level, glucose level, and insulin resistance significantly decreased after metformin treatment. Although participants experienced mild hyperprolactinaemia, metformin effectively counteracted prolactin elevation and improved metabolic parameters. This study highlights metformin’s potential to mitigate antipsychotic-induced adverse effect. Hyperprolactinaemia and metabolic disturbance are prevalent in patients with schizophrenia under olanzapine treatment.Metformin is an effective strategy to reduce prolactin levels in olanzapine-treated patients with schizophrenia.Metformin could improve olanzapine-induced metabolic abnormalities in patients with schizophrenia. Hyperprolactinaemia and metabolic disturbance are prevalent in patients with schizophrenia under olanzapine treatment. Metformin is an effective strategy to reduce prolactin levels in olanzapine-treated patients with schizophrenia. Metformin could improve olanzapine-induced metabolic abnormalities in patients with schizophrenia.
DOI: 10.6084/m9.figshare.30001057.v1
title: The efficacy of metformin in counteracting olanzapine-induced hyperprolactinemia: an open-label prospective study

description: Prolactin elevation is a common adverse effect of antipsychotic medications. The study aimed to explore the potential of metformin in managing olanzapine-induced hyperprolactinaemia. A prospective study was designed to investigate the changes in prolactin levels over an eight-week metformin treatment. Thirty-one patients with schizophrenia (aged 18–60 years) on a stable dose of olanzapine for at least three months were enrolled. Participants received metformin at 1500 mg/day for eight weeks. Prolactin levels and metabolic parameters were measured at baseline and at weeks 2, 4, 6, and 8. After eight weeks of metformin intervention, prolactin levels significantly decreased from 39.7 ± 20.0 ng/mL at baseline to 35.7 ± 15.7 ng/mL (<i>p</i> = 0.005) with a moderate effect size (Cohen’s <i>d</i> = 0.545). Reductions in prolactin levels correlated positively with baseline prolactin levels (<i>r</i> = 0.72, <i>p</i> &lt; 0.001) and baseline glucose levels (<i>r</i> = 0.47, <i>p</i> = 0.008). Body weight, BMI, insulin level, glucose level, and insulin resistance significantly decreased after metformin treatment. Although participants experienced mild hyperprolactinaemia, metformin effectively counteracted prolactin elevation and improved metabolic parameters. This study highlights metformin’s potential to mitigate antipsychotic-induced adverse effect. Hyperprolactinaemia and metabolic disturbance are prevalent in patients with schizophrenia under olanzapine treatment.Metformin is an effective strategy to reduce prolactin levels in olanzapine-treated patients with schizophrenia.Metformin could improve olanzapine-induced metabolic abnormalities in patients with schizophrenia. Hyperprolactinaemia and metabolic disturbance are prevalent in patients with schizophrenia under olanzapine treatment. Metformin is an effective strategy to reduce prolactin levels in olanzapine-treated patients with schizophrenia. Metformin could improve olanzapine-induced metabolic abnormalities in patients with schizophrenia.
DOI: 10.6084/m9.figshare.30152782
title: Metformin usage in the treatment of risperidone induced hyperprolactinemia in an adolescent patient with bipolar disorder type 1: a case report

description: Antipsychotic drugs are used in the treatment of many mental disorders, especially psychotic disorders, bipolar disorders and neurodevelopmental disorders in children and adolescents. Antipsychotics, along with their effectiveness in treatment, have also been associated with a number of adverse effects. One of these is hyperprolactinaemia (hyperPRL) that occurs with antipsychotics. This situation is thought to be due to dopamine blockade in the tuberoinfundibular pathway, which has an effect on prolactin release. Hereby, we present a 15 year old female adolescent bipolar disorder type 1 case who developed hyperprolactinaemia with risperidone treatment which was ameliorated with metformin use (850–2000 mg/day). Although there are studies showing that metformin can be used in the treatment of hyperprolactinaemia, as far as we know, there are not enough studies on the use of metformin in adolescents. Future studies are needed to elucidate the risk factors, aetiological mechanism and treatment alternatives of this adverse effect, which occurs due to antipsychotics and may negatively affect medication compliance.
DOI: 10.6084/m9.figshare.30152782.v1
title: Metformin usage in the treatment of risperidone induced hyperprolactinemia in an adolescent patient with bipolar disorder type 1: a case report

description: Antipsychotic drugs are used in the treatment of many mental disorders, especially psychotic disorders, bipolar disorders and neurodevelopmental disorders in children and adolescents. Antipsychotics, along with their effectiveness in treatment, have also been associated with a number of adverse effects. One of these is hyperprolactinaemia (hyperPRL) that occurs with antipsychotics. This situation is thought to be due to dopamine blockade in the tuberoinfundibular pathway, which has an effect on prolactin release. Hereby, we present a 15 year old female adolescent bipolar disorder type 1 case who developed hyperprolactinaemia with risperidone treatment which was ameliorated with metformin use (850–2000 mg/day). Although there are studies showing that metformin can be used in the treatment of hyperprolactinaemia, as far as we know, there are not enough studies on the use of metformin in adolescents. Future studies are needed to elucidate the risk factors, aetiological mechanism and treatment alternatives of this adverse effect, which occurs due to antipsychotics and may negatively affect medication compliance.
DOI: 10.15151/esrf-es-2268263649
title: ex situ flat samples measurements

description: measurement of various samples ex situ (metallic samples with coating, single crystals...)
DOI: 10.6084/m9.figshare.30155806
title: Asenapine for aggressive behaviours in psychiatric disorders: a systematic review of efficacy and real-world effectiveness

description: Clinical decision-making for the pharmacological treatment of aggressive behaviour in psychiatry remains challenging. Asenapine, a second-generation antipsychotic with a higher affinity for dopamine D4 than for D2 receptors, may become a treatment option, although this remains to be demonstrated. A systematic search was conducted across biomedical databases according to PRISMA Reporting Items for Systematic Review. We aimed to examine the efficacy and effectiveness of asenapine in the management of aggressive behaviours including psychomotor agitation, hostility, irritability, anger, impulsivity, self-harm, behavioural disinhibition, as well as physical and verbal aggression, across psychiatric disorders. Of the 12 studies included, four reported asenapine’s efficacy in aggressive behaviours compared to placebo, and five described the effectiveness in uncontrolled settings. Three studies found no advantages over olanzapine. Major evidence supports asenapine’s efficacy in reducing psychomotor agitation and hostility, with benefits independent of its anti-manic and antipsychotic effects. Asenapine may be a viable option for the treatment of psychomotor agitation and hostility, although more head-to-head trials are needed to clarify its efficacy relative to other antipsychotics. Since the evidence of efficacy in other aggressive domains and diagnoses is still limited, clinicians should primarily consider the tolerability profile to guide their prescription.
DOI: 10.6084/m9.figshare.30155806.v1
title: Asenapine for aggressive behaviours in psychiatric disorders: a systematic review of efficacy and real-world effectiveness

description: Clinical decision-making for the pharmacological treatment of aggressive behaviour in psychiatry remains challenging. Asenapine, a second-generation antipsychotic with a higher affinity for dopamine D4 than for D2 receptors, may become a treatment option, although this remains to be demonstrated. A systematic search was conducted across biomedical databases according to PRISMA Reporting Items for Systematic Review. We aimed to examine the efficacy and effectiveness of asenapine in the management of aggressive behaviours including psychomotor agitation, hostility, irritability, anger, impulsivity, self-harm, behavioural disinhibition, as well as physical and verbal aggression, across psychiatric disorders. Of the 12 studies included, four reported asenapine’s efficacy in aggressive behaviours compared to placebo, and five described the effectiveness in uncontrolled settings. Three studies found no advantages over olanzapine. Major evidence supports asenapine’s efficacy in reducing psychomotor agitation and hostility, with benefits independent of its anti-manic and antipsychotic effects. Asenapine may be a viable option for the treatment of psychomotor agitation and hostility, although more head-to-head trials are needed to clarify its efficacy relative to other antipsychotics. Since the evidence of efficacy in other aggressive domains and diagnoses is still limited, clinicians should primarily consider the tolerability profile to guide their prescription.